论文部分内容阅读
消化道恶性肿瘤淋巴转移是其主要扩散方式之一,是手术治疗不彻底、术后复发的重要原因.新辅助化疗可以降低肿瘤细胞的生物活性,减少术中癌细胞种植,降低术后复发.淋巴化疗作为新辅助化疗一种形式为越来越多临床工作者关注和采用.1 淋巴化疗的意义消化道恶性肿瘤淋巴化疗可进一步提高生存率.资料表明,早期胃癌粘膜类型淋巴转移率为0～3%,粘膜下型为20%,进展期胃癌淋巴结转移为70%左右.根治性切除病例无淋巴结转移者5年生存率为82.5%,1～4个淋巴结转移者为49.1%,5～9个者为34.5%,10个以上者9%.胃癌根治术后,淋巴结复发为死亡原因者占所有死亡患者的20%.结肠癌术后局部复发占全部复发的近40%,而直肠的局部复发占全部复发的52.6%,手术未能彻底清扫转移至淋巴内的癌细胞是局部复发的重要原因.有效的淋巴化
Lymphatic metastasis of gastrointestinal cancer is one of the main diffusion methods. It is an important cause of incomplete surgical treatment and postoperative recurrence. Neoadjuvant chemotherapy can reduce the biological activity of tumor cells, reduce the implantation of cancer cells, and reduce postoperative recurrence. Lymphatic chemotherapy as a form of neoadjuvant chemotherapy is becoming more and more important for clinicians to follow and adopt.1 Significance of Lymphatic Chemotherapy Lymphatic chemotherapy for lymphoma of the digestive tract can further improve survival. The data suggest that the gastric cancer lymph node metastasis rate is 0 ~3%, submucosal type was 20%, lymph node metastasis of advanced gastric cancer was about 70%. 5-year survival rate of radical resection cases without lymph node metastasis was 82.5%, 49.1% for 1 to 4 lymph node metastases, 5 ~ 90% were 34.5%, 10% were 9%. After radical gastrectomy, recurrence of lymph nodes was the cause of death 20% of all deaths. Local recurrence after colon cancer accounted for nearly 40% of all recurrences, and rectal Local recurrence accounted for 52.6% of all recurrences. Surgery failed to completely clean cancer cells that metastasized to the lymph is an important cause of local recurrence. Effective lymphatic metastasis